Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.41 |
| ▸ | CNR1 | P21554 | 3/20 | 0.41 |
| ▸ | CNR2 | P34972 | 3/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PYGB | P11216 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20942603 | 1.00 | TRPV1 (0.41) | TRPV1CNR1CNR2TAS1R3TAS1R1 | |
| SCHEMBL828065 | 1.00 | TRPV1 (0.41) | TRPV1CNR1CNR2TAS1R3TAS1R1 | |
| SCHEMBL18361602 | 0.96 | TRPV1 (0.41) | TRPV1CNR1CNR2ALDH1A1USP2 | |
| SCHEMBL21258467 | 0.88 | TRPV1 (0.43) | TRPV1CNR1CNR2MTNR1AMTNR1B | |
| SCHEMBL24022485 | 0.88 | TRPV1 (0.43) | TRPV1CNR1CNR2MTNR1AMTNR1B | |
| SCHEMBL22858805 | 0.85 | TRPV1 (0.50) | TRPV1CNR1CNR2MTNR1AMTNR1B | |
| SCHEMBL22859155 | 0.85 | TRPV1 (0.50) | TRPV1CNR1CNR2MTNR1AMTNR1B | |
| SCHEMBL4342108 | 0.85 | TRPV1 (0.50) | TRPV1CNR1CNR2MTNR1AMTNR1B | |
| SCHEMBL5021846 | 0.83 | USP2 (0.44) | TAS1R3TAS1R1TAS1R2ALDH1A1USP2 | |
| SCHEMBL22858735 | 0.81 | TRPV1 (0.50) | TRPV1CNR1CNR2SMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | TRPV1 4626/4885CNR1 4281/4885CNR2 3535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.